Swiss CMO Lonza, which has been searching for a game-changing M&A deal—having let Catalent get away—may have found one in contractor Capsugel.
Lonza today acknowledged it is in negotiations with the the investment firm KKR regarding the potential acquisition of Capsugel. KKR bought Capsugel from Pfizer in 2011 for $2.38 billion.
“Lonza confirms that it has expressed a strong interest in this successful company as it would fit perfectly with Lonza’s healthcare continuum strategy and strengthen its position as leading supplier to a number of important healthcare markets. A successful acquisition would be value adding and be within Lonza’s stated acquisition criteria,” the statement said.
Capsugel, which sells both empty two-piece capsules and finished dose products, has 13 manufacturing sites around the world, three R&D facilities, and claims 4,000 customers. That would be added to Lonza’s 11 contract development and manufacturing sites worldwide. A deal could top $5 billion, sources told Reuters. Lonza cautioned in its statement that there is no guarantee an acquisition will be completed.
Sources tell The Wall Street Journal that KKR has been holding an auction for the company and that Lonza is the leading candidate, but that another company could yet snatch it away from Lonza. Reports last spring said KKR was looking to sell the capsule maker and that companies checking it out included Becton Dickinson, Thermo Fisher Scientific, Bayer and Catalent.
Catalent’s name actually came up in a similar context with Lonza’s when it was reported some months back that the Swiss CMO was trying to buy the Somerset, New Jersey, company. However, sources told FiercePharmaManufaturing two months ago that a deal did not materialize.
Catalent CFO Matt Walsh told investors in August that Catalent expects M&A to play a part in its growth as the market consolidates. A month later it bought San Diego-based Pharmtek to get spray drying technology, then just a couple of weeks ago made its own move into capsule manufacturing with an agreement to buy Canada-based Accucaps, a developer and manufacturer of over-the-counter, high potency and conventional pharmaceutical softgels.
For several years now there has been a mantra in the contract manufacturing space of “bulk up or face being bought out.” Patheon, which hooked up with DSM Pharmaceutical Products in 2014, spent a year pulling off deals to create a multibillion-dollar CDMO operation. Durham, North Carolina-based Patheon recently added to its manufacturing capacity with a deal to buy a U.S. API plant from Roche. Sweden’s Recipharm has been making acquisitions, including a $205 million deal earlier this year for India’s Kemwell.
By Eric Palmer
Source: Fierce Pharma
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
